Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
2.
Pneumologia ; 65(1): 39-44, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27209840

RESUMO

Williams-Beuren syndrome (WBS) is a rare genetic disease with a distinctive constellation of clinical findings. The disease can be diagnosed clinically by a recognizable pattern of malformations, including cardiovascular malformations, a characteristic facial dysmorphism, as well as neurological and cognitive features. We present the case of a 23-years-old woman repeatedly admitted to Pulmonology Clinic for massive hemoptysis. Diagnosis of Williams-Beuren syndrome was revealed by clinical findings and confirmed by CT-angiography data of cardiovascular malformations and fluorescence in situ hybridization (FISH) genetic test. WBS is a multisystem disorder and usually is recognized by clinician. If clinical impression is not clearly consistent with WBS, FISH remains the most widely used test.


Assuntos
Anormalidades Múltiplas , Elastina/genética , Hemoptise/genética , Quinases Lim/genética , Síndrome de Williams/genética , Anormalidades Múltiplas/genética , Adulto , Angiografia/métodos , Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos/genética , Biomarcadores/sangue , Deleção Cromossômica , Face/anormalidades , Feminino , Comunicação Interatrial/genética , Humanos , Hipertensão Pulmonar/genética , Deficiência Intelectual/genética , Doenças Raras , Recidiva , Síndrome de Williams/diagnóstico
3.
Pneumologia ; 65(4): 216-21, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-29542908

RESUMO

Bronchiectasis, defined as an abnormal and irreversible dilatation of the bronchi, frequently associated with inflammation, is the most common complication of recurrent infections. Effective pulmonary immunity is necessary to prevent chronic bronchial damage due to bacterial infection. Primary immune deficiencies comprise a heterogeneous group of genetically determined disorders that affect development and/or the function of innate or adaptive immunity. In multiple series reported in literature, common variable immunodeficiency (CVID), X-linked agammaglobulinemia (XLA) and chronic granulomatous disease (CGD) were the most common forms of primary immune deficiencies (PIDs) associated with bronchiectasis (1,15). Despite advances in the molecular knowledge of PIDs during the past two decades, there are many undiagnosed or late diagnosed patients (6,14). We report a case of Bruton's disease late diagnosed, already with bronchiectasis, with an early onset of recurrent respiratory infections.


Assuntos
Agamaglobulinemia/genética , Bronquiectasia/genética , Doenças Genéticas Ligadas ao Cromossomo X/genética , Adulto , Agamaglobulinemia/complicações , Agamaglobulinemia/diagnóstico , Agamaglobulinemia/imunologia , Índice de Massa Corporal , Bronquiectasia/diagnóstico , Bronquiectasia/imunologia , Diagnóstico Diferencial , Progressão da Doença , Doenças Genéticas Ligadas ao Cromossomo X/complicações , Doenças Genéticas Ligadas ao Cromossomo X/diagnóstico , Doenças Genéticas Ligadas ao Cromossomo X/imunologia , Humanos , Masculino , Neutropenia/genética , Fatores de Risco
4.
Pneumologia ; 64(1): 46-50, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26016056

RESUMO

Pulmonary toxicity is a rare side effect of interferon treatment with a wide spectrum of lung tissue conditions, including interstitial pneumonitis, pulmonary sarcoidosis, bronchiolitis obliterans organizing pneumonia, pleural effusion, exacerbation of bronchial asthma, reversible pulmonary hypertension and acute respiratory distress syndrome. We report a case of interstitial pneumonitis in a patient treated with pegylated interferon α2-a and ribavirin for chronic hepatitis C virus infection, genotype 1. The case was marked by progression of the respiratory symptoms even after the withdrawn of the pegylated interferon. One-year treatment with systemic corticosteroid ensured a considerable resorption of CT lesions but only a moderate improvement of symptoms and diffusion capacity without a complete recovery.


Assuntos
Antivirais/efeitos adversos , Glucocorticoides/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Interferon-alfa/efeitos adversos , Doenças Pulmonares Intersticiais/induzido quimicamente , Doenças Pulmonares Intersticiais/tratamento farmacológico , Polietilenoglicóis/efeitos adversos , Antivirais/administração & dosagem , Progressão da Doença , Feminino , Glucocorticoides/administração & dosagem , Humanos , Interferon-alfa/administração & dosagem , Doenças Pulmonares Intersticiais/diagnóstico , Pessoa de Meia-Idade , Polietilenoglicóis/administração & dosagem , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos adversos , Ribavirina/administração & dosagem , Fatores de Tempo , Resultado do Tratamento
5.
Pneumologia ; 63(3): 156, 159-63, 2014.
Artigo em Ro | MEDLINE | ID: mdl-25420290

RESUMO

Cryptococcus is a leading mycological cause of morbidity among HIV-infected patients. In many patients, cryptococcosis is the first indication of AIDS. The lung is invariably the portal of entry and initial site of infection for C. neoformans. In immunosuppressed patients all areas of the body can be infected, and central nervous sistem involvement is the most severe complication. Cryptococcosis is an important fungal infection thatshould be considered in the differential diagnosis of the pulmonary infiltrates in the immunosuppressed patient. The purpose of this paper is to review the current knowledge of the management and treatment strategies of cryptococcosis.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/diagnóstico , Criptococose/diagnóstico , HIV-1 , Hospedeiro Imunocomprometido , Pneumopatias Fúngicas/diagnóstico , Infecções Oportunistas Relacionadas com a AIDS/complicações , Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Antifúngicos/uso terapêutico , Criptococose/complicações , Criptococose/tratamento farmacológico , Cryptococcus neoformans/isolamento & purificação , Humanos , Pneumopatias Fúngicas/tratamento farmacológico , Pneumopatias Fúngicas/microbiologia , Meningite Criptocócica/diagnóstico , Meningite Criptocócica/tratamento farmacológico , Fatores de Risco , Fatores de Tempo
6.
Early Sci Med ; 17(1-2): 112-33, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22702168

RESUMO

The natural histories contained in Francis Bacon's Historia naturalis et experimentalis seem to differ from the model presented in De augmentis scientiarum and the Descriptio globi intellectualis in that they are focused on the defining properties of matter, its primary schematisms and the spirits. In this respect, they are highly speculative. In this paper I aim to describe the Historia naturalis et experimentalis as a text about matter theory, the histories of which are ascending from what is most evident to the senses to what is least accessible to them. Moreover, the Latin natural histories are parts of a methodological procedure in which the provisional rules and axioms obtained in one history can be used as theoretical assumptions for another history, thereby permitting one to delve ever more profoundly into the structure of nature.


Assuntos
História Natural/história , Filosofia/história , Inglaterra , História do Século XVII
7.
Pneumologia ; 61(1): 37-43, 2012.
Artigo em Ro | MEDLINE | ID: mdl-22545488

RESUMO

AIM: To compare the efficiency of some prognostic scores in patients with severe influenza pneumonias. MATERIALS AND METHODS: The study was performed on a cohort of 75 cases of 2009 AH1N1 influenza associated pneumonias. Clinical and laboratory features at admission were used to calculate retrospectively the following prognostic scores: SCAP (Severe Community Acquired Pneumonia), CAP-PIRO (Community Acquired Pneumonia--Predisposition Infection Reaction, Organ failure), SMRT-CO (Systolic blood pressure, Multilobar infiltrates, Respiration rate, Tachycardia, Confusion, Oxygen), IDSA/ATS (Infectious Diseases Society of America/American Thoracic Society). The scores were used to assess two different outcomes--death and need for invasive mechanical ventilation (IMV). The performance of the prognostic tools were assessed using the area under receiver operating characteristic (AUC), and the sensitivity and specificity for identifying high risk patients for severe course of pneumonia. RESULTS: IMV was applied in 29 (38.7%) of studied cases, in 15 (20%) the diseases had a fatal outcome. Despite the fact that all scores had a very good discriminatory power in predicting both outcomes (AUC > 0,8), some of them have a very low sensitivity, in classes corresponding to sever pneumonias, in predicting mortality (IDSA/ATS-0%; 95% CI, 0-21.8%), as well as the need for IMV (IDSA/ATS-0%; 95% CI, 0-11.9%); SCAP-58.6% (95% CI, 38.9-76.5%); CAP-PIRO-58,6% (95% CI, 38.9-76.5%). CONCLUSIONS: The CAP-PIRO and SMRT-CO scores were found to have the best performances to predict death from influenza associated severe pneumonias and the last, also in predicting the need for IVM. Other analyzed scores underestimate the risk of occurrence of both assessed outcomes.


Assuntos
Vírus da Influenza A Subtipo H1N1/isolamento & purificação , Influenza Humana/complicações , Pneumonia Viral/virologia , Adulto , Algoritmos , Estudos de Coortes , Cuidados Críticos/estatística & dados numéricos , Feminino , Ventilação de Alta Frequência/métodos , Humanos , Influenza Humana/diagnóstico , Influenza Humana/mortalidade , Influenza Humana/terapia , Masculino , Pessoa de Meia-Idade , Moldávia/epidemiologia , Pneumonia Viral/diagnóstico , Pneumonia Viral/mortalidade , Pneumonia Viral/terapia , Valor Preditivo dos Testes , Prognóstico , Estudos Retrospectivos , Medição de Risco/métodos , Sensibilidade e Especificidade , Índice de Gravidade de Doença , Taxa de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA